Category Archives: Global News Feed

HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease (MRD) liquid biopsy assay to genitourinary (GU) cancers at the 2023 American Urological Association (AUA) Annual Meeting held in Chicago between April 28 to May 1, 2023.

The rest is here:
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events

View post:
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with...

LA JOLLA, Calif., April 30, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of advanced nonalcoholic steatohepatitis (NASH).

See original here:
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™

Read this article:
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™

More here:
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the promotion of Pascal Qian to the position of Chief Commercial Officer. He will continue to also serve as the company’s China General Manager.

Read more from the original source:
LianBio Promotes Pascal Qian to Chief Commercial Officer

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 2:30 p.m. ET.

More here:
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

Data accepted as AAN Late-Breaking Abstract Data accepted as AAN Late-Breaking Abstract

Excerpt from:
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The...

Oslo, 21 April 2023: On the basis of the approval by the General Meeting on 20 April 2023 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to issue new shares to employees under a long-term incentive program, the Board of Directors has resolved to issue share options to employees in the Company.

Read the original:
Ultimovacs ASA - Share Option Program

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. Details of participation are as follows:

Originally posted here:
Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit